Dr. Wiezorek served as Executive Medical Director, Global Development, at Amgen. In this position, he was responsible for global oversight of the clinical strategy for the immunotherapy (including blinatumomab and talimogene laherparepvec), angiogenesis, and denosumab oncology product areas. Previously, he was Amgen’s Global Development Leader for multiple programs encompassing phase one through phase four trials. In these roles, Dr. Wiezorek worked closely with global regulatory agencies, and he was the development lead for the approval of Vectibix in combination with chemotherapy in Europe. Prior to joining Amgen, he investigated the role of nuclear factor-kappaB in cellular proliferation and cancer pathogenesis in the laboratory of Dr. David Baltimore at the California Institute of Technology. Dr. Wiezorek is author or co-author on more than 30 peer-reviewed articles and presentation abstracts. He received his B.A. degree in biophysics from the University of Pennsylvania and his M.D. degree from Columbia University, trained in internal medicine at Stanford University and completed a fellowship in oncology at the University of California, Los Angeles.